Using documents obtained from litigation about Paxil (paroxetine), an antidepressant sold by GlaxoSmithKline, the Project on Government Oversight (POGO) discovered that the National Institutes of Health (NIH) had funded researchers who use ghostwriters to write journal articles and other scientific communications. POGO used this information to ask Francis Collins, NIH Director, to take a stance against ghostwriting including issuing policies to require institutions to ban ghostwriting, making NIH funding contingent upon periodic certification from institutions that prohibit ghostwriting and that enforcement mechanisms such as disciplinary action and dismissal are in place.
The Paxil lawsuits:
Cunningham v. SmithKline Beecham Corp., U.S. District Court, Northern District of Indiana, Case No. 2:07-CV-174 (2006). Complaint;
Smith v. SmithKline Beecham Corp., Superior Court of California, Orange County, Case No. 04CC00590 (2004);
Bratt v. SmithKline Beecham Corp., United States District Court, Eastern District of California, Case No. 2:06-cv-1063 (2006);
Forst v. SmithKline Beecham Corp., United States District Court, Eastern District of Wisconsin, Case No. 07-CV-612 (2007);
Steinberg v. SmithKline Beecham Corp., Superior Court of California, County of Santa Clara, Case No. 1-04-CV-029096 (2004)